Determination of MDMA, MDA, MDEA and MBDB in oral fluid using high performance liquid chromatography with native fluorescence detection.
This paper describes the analytical methodology for the determination of MDMA, MDA, MDEA and MBDB in oral fluid. After a liquid-liquid extraction, the analysis was carried out by high performance liquid chromatography (HPLC), with fluorescence detection. The detector wavelength was fixed at 285 nm for excitation and 320 nm for emission. The mobile phase, a mixture of phosphate buffer (pH=5) and acetonitrile (75:25), and the column, Kromasil 100 C8 5 microm 250 mm x 4.6mm, allowed good separation of the compounds in an isocratic mode in only 10 min. The method was validated and showed good limits of detection (2 ng/mL) and quantitation (10 ng/mL) for all the amphetamine derivatives. No interfering substances were detected. A stability study of these compounds in oral fluid stored at three different temperatures (-18, 4 and 20 degrees C) over 10 weeks was conducted, showing a time-dependent degradation of the four compounds.
Concheiro
Marta
M
Forensic Toxicology Service, Institute of Legal Medicine, University of Santiago de Compostela, c/ San Francisco s/n, 15782 Santiago de Compostela, Spain.
de Castro
Ana
A
Quintela
Oscar
O
López-Rivadulla
Manuel
M
Cruz
Angelines
A
D015104:3,4-Methylenedioxyamphetamine / Q000031:analogs & derivatives* / Q000032:analysis*; D002851:Chromatography, High Pressure Liquid; D005554:Forensic Medicine / Q000379:methods; D006213:Hallucinogens / Q000032:analysis*; D006801:Humans; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000032:analysis*; D012463:Saliva / Q000737:chemistry*; D013050:Spectrometry, Fluorescence; D015813:Substance Abuse Detection / Q000379:methods*
D006213:Hallucinogens; C051570:N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine; D015104:3,4-Methylenedioxyamphetamine; D018817:N-Methyl-3,4-methylenedioxyamphetamine